SAN DIEGO, CA, USA I September 9, 2014 I Ansun BioPharma announced today a late breaker oral presentation titled “DAS181 for the Treatment of Parainfluenza Virus Infections in 16 Hematopoietic Stem Cell Transplant Recipients” by Dr. Mirella Salvatore of Weill Cornell Medical College. The presentation examined the safety, clinical and virologic outcomes of transplant patients infected with the parainfluenza virus and treated with DAS181 (ParaDase™).
ParaDaseTM is an investigational drug which is designed to act locally on the respiratory surface to prevent attachment of the virus to its receptor. Parainfluenza virus infections are one of the most common respiratory infections in immunocompromised patients, and there are no current licensed vaccines or antiviral drugs for this virus.
Dr. Rosemary Soave, Principal Investigator of the team at Weill Cornell Medical College, commented: “Our data suggests that ParaDaseTM may be a safe and effective therapy for PIV LRTI infections in HSCT recipients. This infection results in significant morbidity and mortality in these patients and effective treatments are urgently needed”. “We are committed to determine the efficacy of ParaDaseTM in patients with severe parainfluenza infection and will continue to work with the FDA on the development of this important drug in an area of unmet medical need,” said Dr. Ronald Moss, CEO of Ansun BioPharma.
The company also announced new data suggesting preclinical activity of DAS181 against JC and BK viruses, two viruses that occur in immunocompromised patients. Dr. Sabrina Tan, Assistant Professor of Medicine at Harvard Medical School, presented this data at ICAAC in an abstract titled “DAS181 Anti-viral Activities Against The Human Polyomaviruses JC And BK”.
About Ansun BioPharma
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.
SOURCE: Ansun BioPharma
Post Views: 137
SAN DIEGO, CA, USA I September 9, 2014 I Ansun BioPharma announced today a late breaker oral presentation titled “DAS181 for the Treatment of Parainfluenza Virus Infections in 16 Hematopoietic Stem Cell Transplant Recipients” by Dr. Mirella Salvatore of Weill Cornell Medical College. The presentation examined the safety, clinical and virologic outcomes of transplant patients infected with the parainfluenza virus and treated with DAS181 (ParaDase™).
ParaDaseTM is an investigational drug which is designed to act locally on the respiratory surface to prevent attachment of the virus to its receptor. Parainfluenza virus infections are one of the most common respiratory infections in immunocompromised patients, and there are no current licensed vaccines or antiviral drugs for this virus.
Dr. Rosemary Soave, Principal Investigator of the team at Weill Cornell Medical College, commented: “Our data suggests that ParaDaseTM may be a safe and effective therapy for PIV LRTI infections in HSCT recipients. This infection results in significant morbidity and mortality in these patients and effective treatments are urgently needed”. “We are committed to determine the efficacy of ParaDaseTM in patients with severe parainfluenza infection and will continue to work with the FDA on the development of this important drug in an area of unmet medical need,” said Dr. Ronald Moss, CEO of Ansun BioPharma.
The company also announced new data suggesting preclinical activity of DAS181 against JC and BK viruses, two viruses that occur in immunocompromised patients. Dr. Sabrina Tan, Assistant Professor of Medicine at Harvard Medical School, presented this data at ICAAC in an abstract titled “DAS181 Anti-viral Activities Against The Human Polyomaviruses JC And BK”.
About Ansun BioPharma
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.
SOURCE: Ansun BioPharma
Post Views: 137
